Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US12178829B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2023 |
| Grant date | Dec 31, 2024 |
| Priority date | — |
| Expiry date | Oct 27, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate polymeric therapeutic or diagnostic compound to off-target sites. Mannosylated carbohydrate polymers are synthesized to be modified to be either polyanionic (i.e., net negatively charged) or electrostatically neutral, and using these polyanionic or neutral mannosylated carbohydrate polymers as competitors for polycationic (i.e., net positively charged) mannosylated carbohydrate polymers carrying small molecule drug payloads or imaging moieties to CD206 expressing cells in target tissues, such as tumors or other sites of inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.